Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
Iovance Biotherapeutics raised its full year 2026 total revenue guidance to $410-$420 million, up $55 million or ~15% at the midpoint from the prior $350-$370 million range. The raise is driven by strong U.S. demand for Amtagvi (lifileucel) and Proleukin, with the new midpoint implying nearly 60% annual revenue growth.
Key figures
- Guidance
- FY2026 total revenue raised to $410-$420 million from prior $350-$370 million; midpoint up $55 million (~15%); implies nearly 60% annual growth
- Atc count
- ~100 authorized treatment centers, targeting at least 110 by year-end 2026
- New guidance low
- 410000000
- Midpoint increase
- $55 million (~15%)
- New guidance high
- 420000000
- Prior guidance low
- 350000000
- Q2 product revenue
- 99300000
- Prior guidance high
- 370000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.